We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
06 May 2019
The Federal Court of Appeal has dismissed Apotex's appeal of a judicial review decision of the Therapeutic Products Directorate, which required Apotex to submit additional information concerning products manufactured or tested in Apotex's facilities in India (for further details please see "Apotex's appeal in judicial review of decision seeking further information from India facilities dismissed").
The Federal Court of Appeal found that the Federal Court made no reviewable error in its conclusion that the Therapeutic Products Directorate's decision was not improperly motivated. On 22 February 2019 the Supreme Court dismissed Apotex's application for leave to appeal (docket 38336).
For further information on this topic please contact Urszula Wojtyra at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email (email@example.com). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.